Nano-crystallization of flubendazole for enhanced dissolution rate and improved in vivo efficacy against Trichinella spiralis

References

• Alshaikh RA, Essa EA, El Maghraby GM. 2020. Preparation of stabilized submicron fenofibrate crystals on niacin as a hydrophilic hydrotropic carrier. Pharm Dev Technol. 25(2):168–177.
   PubMed Web of Science ®Google Scholar
• Amin K, Dannenfelser RM, Zielinski J, Wang B. 2004. Lyophilization of polyethylene glycol mixtures. J Pharm Sci. 93(9):2244–2249.
   PubMed Web of Science ®Google Scholar
• Ashour DS, Abou Rayia DM, Saad AE, El-Bakary RH. 2016. Nitazoxanide anthelmintic activity against the enteral and parenteral phases of Trichinellosis in experimentally infected rats. Exp Parasitol. 170:28–35.
   PubMed Web of Science ®Google Scholar
• Baghel S, Cathcart H, O'Reilly NJ. 2016. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 105(9):2527–2544.‏
   PubMed Web of Science ®Google Scholar
• Chi Y, Xu W, Yang Y, Yang Z, Lv H, Yang S, Lin Z, Li J, Gu J, Hill CL, et al. 2015. Three candesartan salts with enhanced oral bioavailability. Crystal Growth Des. 15(8):3707–3714.
   Web of Science ®Google Scholar
• Chung MS, Joo KH, Quan FS, Kwon HS, Cho SW. 2001. Efficacy of flubendazole and albendazole against Trichinella spiralis in mice. Parasite. 8(2 Suppl):S195–S198.
   PubMedGoogle Scholar
• Daebis NAO, El-Massik M, Abdelkader H. 2015. Formulation and characterization of itraconazole oral nanosuspension: methyl cellulose as promising stabilizer. J Drug Develop Clin Trials. 1(1):102.‏
   Google Scholar
• de Araujo GLB, Ferreira FF, Bernardes CES, Sato JAP, Gil OM, de Faria DLA, Loebenberg R, Byrn SR, Ghisleni DDM, Bou-Chacra NA, et al. 2018. A new thermodynamically favored flubendazole/maleic acid binary crystal form: structure, energetics, and in silico PBPK model-based investigation. Crystal Growth Des. 18(4):2377–2386.
   Web of Science ®Google Scholar
• de Assis JMC, Barbosa EJ, Bezzon VDN, Lourenço FR, Carvalho FMS, Matos JR, Araci Bou-Chacra N, Benmore CJ, Byrn SR, Costa FN, et al. 2022. Hot-melt extrudability of amorphous solid dispersions of flubendazole-copovidone: an exploratory study of the effect of drug loading and the balance of adjuvants on extrudability and dissolution. Int J Pharm. 614:121456.
   PubMedGoogle Scholar
• de Souza Gonçalves D, Yukuyama MN, Miyagi MYS, Silva TJV, Lameu C, Bou-Chacra NA, de Araujo GLB. 2023. Revisiting flubendazole through nanocrystal technology: statistical design, characterization and its potential inhibitory effect on xenografted lung tumor progression in mice. J Clust Sci. 34(1):261–272.
   Web of Science ®Google Scholar
• Dunn IJ, Wright KA. 1985. Cell injury caused by Trichinella spiralis in the mucosal epithelium of B10A mice. J Parasitol. 71(6):757–766.
   PubMed Web of Science ®Google Scholar
• Eid RK, Ashour DS, Essa EA, El Maghraby GM, Arafa MF. 2020. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis. Carbohydr Polym. 232:115826.
   PubMed Web of Science ®Google Scholar
• El-Gizawy SA, Osman MA, Arafa MF, El Maghraby G. 2015. Aerosil as a novel co-crystal co-former for improving the dissolution rate of hydrochlorothiazide. Int J Pharm. 478(2):773–778.
   PubMedGoogle Scholar
• Elmehy DA, Hasby Saad MA, El Maghraby GM, Arafa MF, Soliman NA, Elkaliny HH, Elgendy DI. 2021. Niosomal versus nano-crystalline ivermectin against different stages of Trichinella spiralis infection in mice. Parasitol Res. 120(7):2641–2658.
   PubMed Web of Science ®Google Scholar
• El-Temsahi MM, El-Mansoury ST. 1995. The effect of flubendazole on the course of Trichinella spiralis infection in mice: parasitological study. J Egypt Soc Parasitol. 25(2):453–459.
   PubMedGoogle Scholar
• Essa EA, Elmarakby AO, Donia AM, El Maghraby GM. 2017. Controlled precipitation for enhanced dissolution rate of flurbiprofen: development of rapidly disintegrating tablets. Drug Dev Ind Pharm. 43(9):1430–1439.
   PubMed Web of Science ®Google Scholar
• Farhadi M, Haniloo A, Rostamizadeh K, Faghihzadeh S. 2018. Efficiency of flubendazole-loaded mPEG-PCL nanoparticles: a promising formulation against the protoscoleces and cysts of Echinococcus granulosus. Acta Trop. 187:190–200.
   PubMed Web of Science ®Google Scholar
• Guo M, Fu Q, Wu C, Guo Z, Li M, Sun J, He Z, Yang L. 2015. Rod shaped nanocrystals exhibit superior in vitro dissolution and in vivo bioavailability over spherical like nanocrystals: a case study of lovastatin. Colloids Surf B Biointerfaces. 128:410–418.
   PubMed Web of Science ®Google Scholar
• Imono M, Uchiyama H, Yoshida S, Miyazaki S, Tamura N, Tsutsumimoto H, Kadota K, Tozuka Y. 2020. The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: in vitro-in vivo correlation of nanocrystals. Eur J Pharm Biopharm. 146:84–92.
   PubMed Web of Science ®Google Scholar
• Joshi K, Chandra A, Jain K, Talegaonkar S. 2019. Nanocrystalization: an emerging technology to enhance the bioavailability of poorly soluble drugs. Pharm Nanotechnol. 7(4):259–278.
   PubMedGoogle Scholar
• Junyaprasert VB, Morakul B. 2015. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 10(1):13–23.
   Web of Science ®Google Scholar
• Kumar R, Siril PF. 2018. Enhancing the solubility of fenofibrate by nanocrystal formation and encapsulation. AAPS PharmSciTech. 19(1):284–292.
   PubMed Web of Science ®Google Scholar
• Liang LH, Zhao M, Jiang Q. 2002. Melting enthalpy depression of nanocrystals based on surface effect. J Mater Sci Lett. 21(23):1843–1845.
   Google Scholar
• Lipinski CALF. 2002. Poor aqueous solubility—an industry wide problem in drug discovery. Am Pharm Rev. 5(3):82–85.
   Google Scholar
• Ma J, Liang J, Han J, Zheng M, Zhao H. 2019. Solubility modeling and solvent effect of flubendazole in 12 neat solvents. J Chem Eng Data. 64(3):1237–1243.
   Web of Science ®Google Scholar
• Nagarwal RC, Kumar R, Dhanawat M, Das N, Pandit JK. 2011. Nanocrystal technology in the delivery of poorly soluble drugs: an overview. Curr Drug Deliv. 8(4):398–406.
   PubMed Web of Science ®Google Scholar
• Naiem NH, Essa EA, Elmaghraby GM. 2018. Enhancing dissolution rate of indomethacin by in situ crystalization; development of orally disintegrating tablets. Int J Pharm Pharm Sci. 10(5):18–23.
   Google Scholar
• Ndlovu ST, Ullah N, Khan S, Ramharack P, Soliman M, de Matas M, Shahid M, Sohail M, Imran M, Shah SWA, et al. 2019. Domperidone nanocrystals with boosted oral bioavailability: fabrication, evaluation and molecular insight into the polymer-domperidone nanocrystal interaction. Drug Deliv Transl Res. 9(1):284–297.
   PubMed Web of Science ®Google Scholar
• Oncsik T, Trefalt G, Borkovec M, Szilagyi I. 2015. Specific ion effects on particle aggregation induced by monovalent salts within the Hofmeister series. Langmuir. 31(13):3799–3807.
   PubMed Web of Science ®Google Scholar
• Sezgin Z, Yüksel N, Baykara T. 2006. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm. 64(3):261–268.
   PubMed Web of Science ®Google Scholar
• Shah SR, Parikh RH, Chavda JR, Sheth NR. 2014. Glibenclamide nanocrystals for bioavailability enhancement: formulation design, process optimization, and pharmacodynamic evaluation. J Pharm Innov. 9(3):227–237.
   Web of Science ®Google Scholar
• Shakeel F, Faisal MS. 2010. Caffeine: a potential complexing agent for solubility and dissolution enhancement of celecoxib. Pharm Biol. 48(1):113–115.
   PubMed Web of Science ®Google Scholar
• Sharma M, Mehta I. 2019. Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. Sci Rep. 9(1):1–11.
   PubMed Web of Science ®Google Scholar
• Soisuwan S, Teeranachaideekul V, Wongrakpanich A, Langguth P, Junyaprasert VB. 2019. Impact of uncharged and charged stabilizers on in vitro drug performances of clarithromycin nanocrystals. Eur J Pharm Biopharm. 137:68–76.
   PubMed Web of Science ®Google Scholar
• Sudha C, Srinivasan K. 2014. Understanding the effect of solvent polarity on the habit modification of monoclinic paracetamol in terms of molecular recognition at the solvent crystal/interface. Cryst Res Technol. 49(11):865–872.
   Web of Science ®Google Scholar
• Sultan AA, El-Gizawy SA, Osman MA, El Maghraby GM. 2017. Self-dispersing mixed micelles forming systems for enhanced dissolution and intestinal permeability of hydrochlorothiazide. Colloids Surf B Biointerfaces. 149:206–216.
   PubMed Web of Science ®Google Scholar
• Vialpando M, Smulders S, Bone S, Jager C, Vodak D, Van Speybroeck M, Verheyen L, Backx K, Boeykens P, Brewster ME, et al. 2016. Evaluation of three amorphous drug delivery technologies to improve the oral absorption of flubendazole. J Pharm Sci. 105(9):2782–2793.
   PubMed Web of Science ®Google Scholar
• Vigh T, Démuth B, Balogh A, Galata DL, Van Assche I, Mackie C, Vialpando M, Van Hove B, Psathas P, Borbás E, et al. 2017. Oral bioavailability enhancement of flubendazole by developing nanofibrous solid dosage forms. Drug Dev Ind Pharm. 43(7):1126–1133.
   PubMed Web of Science ®Google Scholar
• Wong SM, Kellaway IW, Murdan S. 2006. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm. 317(1):61–68.
   PubMedGoogle Scholar
• Yi Y, Tu L, Hu K, Wu W, Feng J. 2015. The construction of puerarin nanocrystals and its pharmacokinetic and in vivo–in vitro correlation (IVIVC) studies on beagle dog. Colloids Surf B Biointerfaces. 133:164–170.
   PubMed Web of Science ®Google Scholar
• Yukuyama MN, Ishida K, de Araujo GLB, Spadari CdC, de Souza A, Löbenberg R, Henostroza MAB, Folchini BR, Peroni CM, Peters MCC. 2021. Rational design of oral flubendazole-loaded nanoemulsion for brain delivery in cryptococcosis. Colloids Surf, A. 630:127631.
   Google Scholar
• Zhang J, Lv H, Jiang K, Gao Y. 2011. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm. 420(1):180–188.
   PubMed Web of Science ®Google Scholar